Abstracts tagged "interstitial lung disease"

Abstract Number: 1158 • ACR Convergence 2020
Clinical Features and Outcomes in STING-Associated Vasculopathy with Onset in Infancy (SAVI)
Sofia Torreggiani¹, Sara Alehashemi², Jacob Mitchell¹, Gema Souto Adeva¹, Bin Lin¹, Jenna Wade¹, Gina Montealegre Sanchez³, Abdulrahman Alrasheed⁴, Sibel Balci⁵, Roberta Berard⁶, Borzutzky Arturo⁷, Jürgen Brunner⁸, Bjoern Buehring⁹, Al Adba Buthaina¹⁰, Caterina Cancrini¹¹, John Carter¹², Mireia Corbeto Lopez¹³, Fabrizio De Benedetti¹⁴, Huy Do¹⁵, Gregor Dueckers¹⁶, Les Folio¹⁵, Antonella Insalaco¹⁷, Rabia Miray Kisla Ekinci⁵, Michael Miller¹⁸, Marco Montes Cano¹⁹, Marie-Paule Morin²⁰, Seza Ozen²¹, Lucia Pacillo¹¹, Suzanne Ramsey²², Adam Reinhardt²³, Dax Rumsey²⁴, Laisa Santiago²⁵, Grant Schulert²⁶, Benjamin Wright²⁷, Adriana de Jesus²⁸ and Raphaela Goldbach-Mansky²⁹, ¹Translational Autoinflammatory Disease Section (TADS)/NIAID/NIH, Bethesda, MD, ²Translational Autoinflammatory Disease Section (TADS)/NIAID/NIH, Clarksville, MD, ³NIAID/NIH, Rockville, MD, ⁴King Abdullah Specialized Children Hospital, Riyadh, Riyadh, Saudi Arabia, ⁵Department of Pediatric Rheumatology, Cukurova University Faculty of Medicine, Adana, Turkey, ⁶London Health Sciences Centre, London, ON, Canada, ⁷Pontificia Universidad Católica de Chile, Santiago, Chile, ⁸Tirol Kliniken, Innsbruck, Innsbruck, Austria, ⁹Rheumazentrum Ruhrgebiet, Ruhr-University-Bochum, Herne, Germany, ¹⁰Sidra Medicine, Doha, Doha, Qatar, ¹¹Unit of Immune and Infectious Diseases, Scientific Institute for Research and Healthcare (IRCCS) Childrens’ Hospital Bambino Gesù, University Department of Pediatrics (DPUO); Department of Systems Medicine, University of Rome Tor Vergata, Roma, Italy, ¹²University of South Florida, Tampa, FL, ¹³Vall d’Hebron Hospital Universitari, Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain, ¹⁴Division of Rheumatology, Laboratory of Immuno-Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, Italy, ¹⁵Radiology and Imaging Sciences, Clinical Center, NIH, Bethesda, ¹⁶Helios Kliniken - Kinderklinik, HELIOS Klinikum Krefeld, Germany, Krefeld, Germany, ¹⁷Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, Italy, ¹⁸Feinberg School of Medicine, Northwestern University Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, ¹⁹Hospital Universitario Virgen del Rocío, Sevilla, Sevilla, Spain, ²⁰Université de Montréal, CHU Sainte-Justine, Montréal, Canada, ²¹Department of Pediatric Rheumatology, Hacettepe University, Ankara, Turkey, Ankara, Turkey, ²²IWK Health Centre, Dalhousie University, Halifax, NS, Canada, ²³Boys Town National Research Hospital, Omaha, Omaha, NE, ²⁴Alberta Health Services – Edmonton Zone (Stollery Children’s Hospital), University of Alberta, Edmonton, AB, Canada, ²⁵Johns Hopkins All Children's Hospital, St. Petersburg, FL, ²⁶PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²⁷Mayo Clinic, Phoenix, AZ, ²⁸Translational Autoinflammatory Disease Section (TADS)/NIAID/NIH, Silver Spring, MD, ²⁹Translational Autoinflammatory Disease Section (TADS)/NIAID/NIH, Potomac, MD
Background/Purpose: STING-Associated Vasculopathy with Onset in Infancy (SAVI) is an autoinflammatory interferonopathy caused by gain-of-function mutations in STING1, characterized by peripheral vasculopathy and interstitial lung…
Abstract Number: 1606 • ACR Convergence 2020
Mortality with Idiopathic Inflammatory Myositis in an Academic Hospital Setting: A Five-year Retrospective Study
Jaspreet Kaler¹, Zareen Vaghaiwalla², Gurjit Kaeley³ and Myint Thway⁴, ¹University of Florida - Jacksonville, Jacksonville, FL, ²University of Florida Jacksonville, Jacksonville, FL, ³University of Florida College of Medicine - Jacksonville, Jacksonville, FL, ⁴University of Florida- Jacksonville, ponte vedra, FL
Background/Purpose: Idiopathic inflammatory myositis is a diverse group of muscle diseases characterized by muscle inflammation and dysfunction. Approximately 3-7/100,000 cases are diagnosed per year in…
Abstract Number: 0233 • ACR Convergence 2020
Abatacetp in Spanish Patients with Arthritis Rheumatoid and Interstitial Lung Disease. Multicenter Study of 263 Patients
C. Fernandez-Diaz¹, Santos Castañeda², Rafael Melero³, Francisco Miguel Ortiz Sanjuan⁴, Antonio Juan-Mas⁵, Carmen Carrasco Cubero⁶, Raquel Almodovar⁷, Sebastian Rodriguez-Garcia⁸, C. Aguilera-Cros⁹, Ignacio Villa¹⁰, S. Ordoñez¹¹, Enrique Raya¹², C. Ojeda¹³, Manuel Jose Moreno-Ramos¹⁴, Gema Bonilla¹⁵, Susana Romero-Yuste¹⁶, Ana Ruibal-Escribano¹⁷, Jose Luis Andreu Sanchez¹⁸, R. Exposito¹⁹, Javier Loricera²⁰, Natalia Mena-Vazquez²¹, Ana Urriticoechea²², C. Peralta²³, Luis Arboleya²⁴, Francisco Javier Narváez²⁵, O. Maiz²⁶, Julia Fernandez Melon²⁷, P Vela²⁸, Ivan Castellvi²⁹, I. Cabezas³⁰, Alejandra Lopez Robles³¹, Patricia Carreira Delgado³², Juan M. Blanco-Madrigal³³, N. Del-val-del-amo³⁴, E Salgado³⁵, B. Garcia-magallon³⁶, Cristina Hidalgo Calleja³⁷, Mireia Corbeto Lopez³⁸, A. Perez³⁹, S. Castro⁴⁰, Juan Ramón De dios⁴¹, Andrea García Valle⁴², R Lopez⁴³, Angel García Aparicio⁴⁴, EC Cervantes⁴⁵, C Gonzalez⁴⁶, N Alvarez-Rivas⁴⁷, L. Perez⁴⁸, Miguel Ángel González-Gay⁴⁹ and Ricardo Blanco⁵⁰, ¹H. Marqués de Valdecilla, Madrid, Spain, ²Princesa University Hospital, Universidad Autónoma, Madrid, Madrid, Spain, ³CHU. VIgo, Vigo, Spain, ⁴Rheumatology Department, HUP La Fe, Valencia, Spain, ⁵Son Llàzer University Hospital, Mallorca, Spain, ⁶H. Mérida, Mérida, Spain, ⁷Fundación Alcorcón University Hospital, Madrid, ⁸La Princesa University Hospital, Madrid, Spain, ⁹H.Virgen del Rocio, Sevilla, Spain, ¹⁰H. Torrelavega, Santander, Spain, ¹¹H. Arnau Vilanova, LLeida, Spain, ¹²San Cecilio Clinic Universitary Hospital, Granada, Spain, ¹³H. Virgen de la Macarena, Sevilla, Spain, ¹⁴Arrixaca University Hospital, Murcia, ¹⁵Rheumatology, La Paz University Hospital-IdiPAZ, Madrid, Spain, ¹⁶H Pontevedra, Coruna, Spain, ¹⁷Hospital Alfredo Espinosa, Urduliz, Pais Vasco, Spain, ¹⁸Hospital Universitario Puerta de Hierro, Majadahonda, Spain, ¹⁹H. Laredo, Laredo, Spain, ²⁰Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²¹Hospital Regional Universitario de Málaga, Málaga, Spain, ²²Can Misses, Ibiza, Spain, ²³H. Clinico Zaragoza, Zaragoza, Spain, ²⁴H. Oviedo, Oviedo, Spain, ²⁵Hospital Bellvitge, BARCELONA, Spain, ²⁶H. Donosti, Donosti, Spain, ²⁷H. Son Espases, Mallorca, Spain, ²⁸H Alicante, Alicante, Spain, ²⁹Hospital Santa Creu i Sant Pau, Barcelona, Spain, ³⁰H. Río Ortega, Valladolid, Spain, ³¹H. León, León, ³²H. 12 de octubre, Madrid, Spain, ³³Basurto University Hospital, Bilbao, Spain, ³⁴Complejo Hospitalario de Navarra, Pamplona, Spain, ³⁵CHU Ourense, Ourense, Spain, ³⁶H. Huesca, Zaragoza, Spain, ³⁷Hospital Universitario Salamanca, Salamanca, Spain, ³⁸Vall d’Hebron Hospital Universitari, Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain, ³⁹H. Puerta del Mar, Cadiz, Spain, ⁴⁰H. Joan XXIII, Tarragona, Spain, ⁴¹H. Alava, Alava, Spain, ⁴²H. Palencia, Palencia, Spain, ⁴³H. Negrin, Las Palmas, Spain, ⁴⁴H. Mostoles, Madrid, Spain, ⁴⁵H. Santiago de compostela, Santiago, Spain, ⁴⁶H. Valladolid, Valladolid, Spain, ⁴⁷H. S Agustin, Aviles, Spain, ⁴⁸Hospital Universitario Virgen de las Nieves, Granada, Spain, ⁴⁹Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain, ⁵⁰Hospital Universitario Marques de Valdecilla, Santander, Spain
Background/Purpose: To assess the efficacy of abatacept (ABA) in Rheumatoid Arthritis (RA) patients with Interstitial Lung Disease (ILD) (RA-ILD).Methods: Observational multicenter study of RA-ILD patients…
Abstract Number: 1048 • ACR Convergence 2020
Reduced Decline in Forced Vital Capacity in Patients with Progressive Fibrosing Autoimmune Disease-Related Interstitial Lung Diseases (ILDs) Treated with Nintedanib
Eric Matteson¹, Oliver Distler², Jörg HW Distler³, Masataka Kuwana⁴, Janet Pope⁵, James Seibold⁶, Alexandra James⁷, Rozsa Schlenker-Herceg⁸, Klaus Rohr⁷ and Kevin Flaherty⁹, ¹Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA, Rochester, MN, ²Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, Switzerland, Zurich, Switzerland, ³University of Erlangen-Nuremberg, Erlangen, Germany, Erlangen, Germany, ⁴Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Tokyo, Japan, ⁵Department of Medicine, University of Western Ontario, St. Joseph's Health Centre, London, ON, Canada, ⁶Scleroderma Research Consultants LLC, Aiken, South Carolina, USA, Aiken, SC, ⁷Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, ⁸Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, USA, Ridgefield, CT, ⁹Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, MI
Background/Purpose: In the randomized placebo-controlled INBUILD trial in patients with chronic fibrosing ILDs with a progressive phenotype, nintedanib reduced the rate of decline in forced…
Abstract Number: 1171 • ACR Convergence 2020
Under Detection of Interstitial Lung Disease in Juvenile Systemic Sclerosis (jSSc) Utilizing Pulmonary Function Tests. Results from the Juvenile Scleroderma Inception Cohort
Ivan Foeldvari¹, Bernd Hinrichs², Kathryn Torok³, Maria Jose Santos⁴, Ozgur Kasapcopur⁵, Amra Adrovic⁶, Valda Stanevicha⁷, Flavio Sztajnbok⁸, Maria Teresa Terreri⁹, Ana Paula Sakamoto¹⁰, Ekaterina Alexeeva¹¹, Jordi Anton¹², Maria Katsicas¹³, Vanessa Smith¹⁴, Tadej Avcin¹⁵, Edoardo Marrani¹⁶, Mikhail Kostik¹⁷, Thomas Lehman¹⁸, Walter Alberto Sifuentes-Giraldo¹⁹, Simone Appenzeller²⁰, Mahesh Janarthanan²¹, Monika Moll²², Dana Nemcova²³, Dieneke Schonenberg-Meinema²⁴, Cristina Battagliotti²⁵, Lillemor Berntson²⁶, Blanca Bica²⁷, Jürgen Brunner²⁸, Patricia Costa Reis²⁹, Despina Eleftheriou³⁰, Liora Harel³¹, Gerd Horneff³², Tilmann Kallinich³³, Dragana Lazarevic³⁴, Kirsten Minden³⁵, Susan Nielsen³⁶, Farzana Nuruzzaman³⁷, Anjali Patwardhan³⁸, Yosef Uziel³⁹ and Nicola Helmus⁴⁰, ¹Head of the Hamburg Centre for Pediatric and Adolescence Rheumatology, Budapest, Hungary, ²Kinderklinik Heidberg Pulmologie, Hamburg, Germany, ³University of Pittsburgh, Pittsburgh, PA, ⁴Hospital Garcia de Orta, Almada, Portugal, ⁵PRINTO, Istituto Giannina Gaslini, Genova, Italy, ⁶Cerrahpaşa Tıp Fakültesi, Istanbul, Turkey, ⁷Riga Stradins University, Riga, Latvia, ⁸Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ⁹Federal University of São Paulo, São Paulo, Brazil, ¹⁰UNIFESP, Sao Paulo, Brazil, ¹¹Scientific Center of Children’s Health of RAMS, Moscow, Russia, ¹²Sant Joan de Déu Hospital, Madrid, Spain, ¹³Hospital de Pediatria, Buenos Aires, Argentina, ¹⁴Department of Rheumatology, Ghent University Hospital, Department of Internal Medicine, VIB Inflammation Research Centre Ghent University, Ghent, Belgium, ¹⁵Ljubljana University Medical Centre, Ljubljana, Slovenia, ¹⁶University of Florence, Firenze, Italy, ¹⁷Saint-Petersburg State Pediatric Medical University, Saint Petersburg, Russia, ¹⁸Hospital for Special Surgery, New York, ¹⁹Hospital Universitario Ramon y Cajal, Madrid, Spain, ²⁰Unicamp, Campinas, Brazil, ²¹Sri Ramachandra University, Chennai, India, ²²University of Tübingen, Tübingen, Germany, ²³General University Hospital, Prague, Czech Republic, ²⁴Amsterdam UMC, Amsterdam, Netherlands, ²⁵Children's Hospital Dr. Orlando Alassia, Santa Fee, Argentina, ²⁶Uppsala University Hospital, Uppsala, Sweden, ²⁷Hospital Universitário Clementino Fraga Filho (HUCFF/UFRJ), Rio de Janeiro, Brazil, ²⁸Tirol Kliniken, Innsbruck, Innsbruck, Austria, ²⁹Hospital de Santa Maria, Lisbon, Portugal, ³⁰Great Ormond Street Hospital, London, United Kingdom, ³¹Clalit Health Services, Nettnja, Israel, ³²Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, ³³Charite, Berlin, Germany, ³⁴KC Niš, Nis, Serbia, ³⁵Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, ³⁶Rigshospitalet, Copenhagen, Denmark, ³⁷Stony Brook Children's Hospital, Stony Brook, NY, ³⁸University of Missouri, Columbia, ³⁹Meir Medical Center, Kfar Saba, Israel, ⁴⁰Hamburg Centre for Pediatric and Adolescence Rheumatology, Hamburg, Germany
Background/Purpose: Juvenile systemic sclerosis (jSSc) has a prevalence in around 3 in a million children. Pulmonary involvement occurs in approximately 40 % in the international…
Abstract Number: 1695 • ACR Convergence 2020
Anti-Melanoma Differentiation Associated Protein 5 (MDA5) Positive Juvenile Dermatomyositis: Focus on the Lung
David Moreno McNeill¹, Miriah Gillispie-Taylor², Kevin Baszis³, Edouard Sayad¹, Manuel Silva Carmona¹ and Tiphanie Vogel¹, ¹Baylor College of Medicine/Texas Children's Hospital, Houston, TX, ²Baylor College of Medicine, Houston, ³Washington Univ School of Medicine, St Louis, MO
Background/Purpose: A subset of juvenile dermatomyositis (JDM), clinically amyopathic dermatomyositis (CADM), is uncommon and mainly described in adults. CADM is classically characterized by skin ulcerations,…
Abstract Number: 1563 • 2019 ACR/ARP Annual Meeting
Interstitial Lung Disease in Patients with Systemic Lupus Erythematosus: Who Should We Screen?
Muhsen Al-ani¹, Bobby Kwanghoon Han ² and Gregory c Gardner ³, ¹University of Washington, seattle, WA, ²University of Washington, seattle, ³University of Wasshington, seattle
Background/Purpose: Systemic lupus erythematosus (SLE) is a disease with a variety of clinical manifestations but interestingly interstitial lung disease (ILD) is rare. The literature to…
Abstract Number: 2155 • 2019 ACR/ARP Annual Meeting
The Spectrum of Interstitial Lung Disease Associated with Autoimmune Diseases: Data of a 3-Year-Prospective Study from a Referral Center of Lung Transplantation
Sara Remuzgo-Martínez¹, Diana Prieto-Peña ², Mónica Calderón-Goercke ², Victor Manuel Mora Cuesta ³, David Iturbe Fernández ¹, Sonia M. Fernández Rozas ³, Jose Manuel Cifrian Martínez ³ and Miguel Angel González-Gay ⁴, ¹Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain, Santander, Spain, ²Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL; and Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain, Santander, Spain, ³Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL; and Pneumology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain, Santander, Spain, ⁴Universidad de Cantabria and IDIVAL, Hospital Universitario Marqués de Valdecilla, Santander, Spain
Background/Purpose: Interstitial lung disease (ILD) occurs in approximately 15% of patients with autoimmune diseases (AD) [1]. Its presence is associated with an increased risk of…
Abstract Number: 189 • 2019 ACR/ARP Annual Meeting
Validation of Claims-based Algorithms to Identify Interstitial Lung Disease in Patients with Rheumatoid Arthritis
Soo-Kyung Cho¹, Tracy J. Doyle ², Hemin Lee ³, Yinzhu Jin ³, Angela Y. Tong ³, Adrian J. Santiago Ortiz ³, Jeffrey Sparks ⁴ and Seoyoung C. Kim ³, ¹Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ²Brigham and Women's Hospital, Harvard Medical School, Boston, ³Brigham and Women’s Hospital and Harvard Medical School, Boston, ⁴Brigham and Women's Hospital, Boston, MA
Background/Purpose: The prevalence of interstitial lung disease (ILD) among rheumatoid arthritis (RA) patient ranges between 5-10%. ILD leads to high morbidity and mortality in patients…
Abstract Number: 1628 • 2019 ACR/ARP Annual Meeting
Lung Function Decline in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease in the SENSCIS Trial: Subgroup Analysis by Time Since First Non-Raynaud Symptom
Aryeh Fischer¹, Oliver Distler ², Dinesh Khanna ³, Yannick Allanore ⁴, Anna Maria Hoffmann-Vold ⁵, Gabriele Valentini ⁶, Toby Maher ⁷, Martin Aringer ⁸, Leslie Meng ⁹, Margarida Alves ¹⁰, Martina Gahlemann ¹¹, Manuel Quaresma ¹⁰ and Masataka Kuwana ¹², ¹University of Colorado School of Medicine, Denver, Colorado, USA, Denver, CO, ²Dept. of Rheumatology, University Hospital Zürich, Zürich, Switzerland, Zürich, Switzerland, ³Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, ⁴Dept. of Rheumatology A, Descartes University, APHP, Cochin Hospital, Paris, France, Paris, France, ⁵Department of Rheumatology, Oslo University Hospital, Oslo, Norway, Oslo, Norway, ⁶Dipartimento di Medicina di Precisione, II Policlinico U.O. Reumatologia, Napoli, Italy, Napoli, Italy, ⁷National Heart and Lung Institute, Imperial College London, UK and National Institute for Health Research Clinical Research Facility, Royal Brompton Hospital, London, UK, London, United Kingdom, ⁸Division of Rheumatology, Department of Medicine III, University Medical Center & Faculty of Medicine Carl Gustav Carus, TU Dresden, Dresden, Germany, Dresden, Germany, ⁹Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA, Ridgefield, ¹⁰Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, ¹¹Boehringer Ingelheim (Schweiz) GmbH, Basel, Switzerland, Basel, Switzerland, ¹²Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, Bunkyo-ku, Tokyo, Japan
Background/Purpose: Interstitial lung disease (ILD) is a common and usually early manifestation of systemic sclerosis (SSc). Decline in lung function in patients with SSc-ILD is…
Abstract Number: 2298 • 2019 ACR/ARP Annual Meeting
Interstitial Lung Disease Is Associated with Distinct Fine Specificities of Anti-Carbamylated Peptide/Protein Antibodies in Rheumatoid Arthritis
Raul Castellanos-Moreira¹, Sebastian Rodriguez-Garcia ², Virginia Ruiz-Esquide ³, Fernanda Hernández-González ⁴, Marcelo Sánchez ⁵, José Ramírez ⁶, Mariana Benegas ⁵, Carmen Lucena-Pozo ⁴, Carlos Agustí ⁴, Marc Boada ⁷, Odette Viñas ⁸, Estíbaliz Ruiz ⁸, Sergio Prieto-González ⁹, Jose Gomez-Puerta ¹, Jacobo Sellares ⁴, Juan Cañete ¹, Isabel Haro ¹⁰ and Raimon Sanmarti ¹, ¹Department of Rheumatology, Hospital Clínic, Barcelona, Barcelona, Spain, ²Rheumatology Department. Hospital Clínic Barcelona, Barcelona, Spain, ³Department of Rheumatology, Hospital Clínic, Barcelona, Barcelona, Catalonia, Spain, ⁴Department of Pneumology, Hospital Clínic, Barcelona, Barcelona, Spain, ⁵Department of Radiodiagnosis, Hospital Clínic, Barcelona, Barcelona, Spain, ⁶Department of Pathological Anatomy, Hospital Clínic, Barcelona, Barcelona, Spain, ⁷Department of Thoracic Surgery, Hospital Clínic, Barcelona, Barcelona, Spain, ⁸Department of Immunology, Hospital Clínic, Barcelona, Barcelona, Spain, ⁹Department of Systemic Autoimmune Diseases Hospital Clínic, Barcelona, Barcelona, Spain, ¹⁰Unit of Synthesis and Biomedical Applications of Peptides, IQAC CSIC, Barcelona, Barcelona, Spain
Background/Purpose: Interstitial lung disease (ILD) is a common and severe complication of rheumatoid arthritis (RA). It has been associated with the presence of ACPA. Anti-carbamylated…
Abstract Number: 369 • 2019 ACR/ARP Annual Meeting
Methotrexate and Interstitial Lung Disease in Patients with Inflammatory Articular Disease: A Systematic Review
Esteban Rubio¹, Alejandro Muñoz ¹ and Núria Casamira ², ¹Rheumatology Department, University Hospital Virgen del Rocío, Sevilla, Spain, ²Medical Department, Gebro Pharma S.A., Barcelona, Spain
Background/Purpose: Methotrexate (MTX) is a commonly used drug for inflammatory joint diseases. Occasionally, its use has been associated with diffuse interstitial lung disease (DILD) development1. A…
Abstract Number: 1636 • 2019 ACR/ARP Annual Meeting
Effect of Anti-Topoisomerase I Antibody Status on Decline in Lung Function in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease: Data from the SENSCIS Trial
Maureen Mayes¹, Kristin Highland ², Martina Gahlemann ³, Aryeh Fischer ⁴, Ganesh Raghu ⁵, Mannaig Girard ⁶, Margarida Alves ⁷, Susanne Stowasser ⁷, Jörg Distler ⁸, Marco Matucci-Cerinic ⁹, Elizabeth Volkmann ¹⁰, Masataka Kuwana ¹¹ and Oliver Distler ¹², ¹Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, Texas, USA, Houston, TX, ²Cleveland Clinic, Cleveland, Ohio, USA, Cleveland, OH, ³Boehringer Ingelheim (Schweiz) GmbH, Basel, Switzerland, Basel, Switzerland, ⁴University of Colorado School of Medicine, Denver, Colorado, USA, Denver, CO, ⁵University of Washington, Seattle, USA, Seattle, ⁶Boehringer Ingelheim France S.A.S., Reims, France, Reims, France, ⁷Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, ⁸Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, Erlangen, Germany, ⁹University of Florence, Department of Medicine, Florence, Italy, Florence, Italy, ¹⁰University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, ¹¹Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, Bunkyo-ku, Tokyo, Japan, ¹²Dept. of Rheumatology, University Hospital Zürich, Zürich, Switzerland, Zürich, Switzerland
Background/Purpose: The presence of anti-topoisomerase I antibody (ATA) in patients with systemic sclerosis (SSc) has been associated with a greater risk of developing interstitial lung…
Abstract Number: 2339 • 2019 ACR/ARP Annual Meeting
Exposure to Avian and Fungal Antigens in Patients with Rheumatoid Arthritis-AssociatedInterstitial Lung Disease: Something to Keep in Mind
Sebastian Rodriguez-Garcia¹, Raul Castellanos-Moreira ², Fernanda Hernández-González ³, Albert Perez ⁴, Joel Francesqui ⁵, Sandra Cuerpo-Cardeñosa ⁵, Virginia Ruiz-Esquide ⁶, Mariana Benegas ⁷, José Ramírez ⁸, Carmen Lucena-Pozo ³, Carlos Agustí ³, Marc Boada ⁹, Estíbaliz Ruiz ⁴, Odette Viñas ⁴, Sergio Prieto-González ¹⁰, Raimon Sanmarti ¹¹, Gerard Espinosa ¹², Mariona Pascal ¹³, Jose Gomez-Puerta ¹¹, Marcelo Sánchez ⁷ and Jacobo Sellares ³, ¹Rheumatology Department. Hospital Clínic Barcelona, Barcelona, Spain, ²Rheumatology Department. Hospital Clínic Barcelona, Barcelona, Catalonia, Spain, ³Department of Pneumology, Hospital Clínic, Barcelona, Barcelona, Spain, ⁴Department of Immunology, Hospital Clínic, Barcelona, Barcelona, Spain, ⁵Pneumology Department. Hospital Clínic Barcelona, Barcelona, Catalonia, Spain, ⁶Department of Rheumatology, Hospital Clínic, Barcelona, Barcelona, Catalonia, Spain, ⁷Department of Radiodiagnosis, Hospital Clínic, Barcelona, Barcelona, Spain, ⁸Department of Pathological Anatomy, Hospital Clínic, Barcelona, Barcelona, Spain, ⁹Department of Thoracic Surgery, Hospital Clínic, Barcelona, Barcelona, Spain, ¹⁰Department of Systemic Autoimmune Diseases Hospital Clínic, Barcelona, Barcelona, Spain, ¹¹Department of Rheumatology, Hospital Clínic, Barcelona, Barcelona, Spain, ¹²Department of Autoimmune Diseases, Hospital Clínic, Barcelona, Barcelona, Catalonia, Spain, ¹³Immunology Department. Hospital Clínic Barcelona, Barcelona, Catalonia, Spain
Background/Purpose: Rheumatoid arthritis associated interstitial lung disease (RA-ILD) is an extra-articular manifestation with a poor prognosis. In clinical practice, to establish such a diagnosis requires…
Abstract Number: 370 • 2019 ACR/ARP Annual Meeting
Use of Serum Lung Injury Biomarkers for Predicting the Severity of Interstitial Lung Disease in Patients with Connective Tissue Disease Associated Interstitial Lung Disease and Interstitial Pneumonia with Autoimmune Features
Sogol Amjadi¹, Tracy Frech ², Jessica Chan ³, Mary Beth Scholand ⁴, Troy Jaskowski ⁵, Sonia La’ulu ⁵, Jonathan Genzen ⁶, Dorota Lebiedz-Odrobina ⁷ and Ann Tebo ⁶, ¹University of Utah, Department of Internal Medicine, Division of Rheumatology, West Jordan, UT, ²Division of Rheumatology, University of Utah and Salt Lake VAMC, Salt Lake City, UT, ³University of Utah, Department of Radiology, salt lake city, UT, ⁴University of Utah, Department of Internal Medicine, Division of Pulmonary Medicine, salt lake city, UT, ⁵ARUP Institute for Clinical and Experimental Pathology, salt lake city, UT, ⁶ARUP Institute for Clinical and Experimental Pathology , University of Utah, Department of Pathology, salt lake city, UT, ⁷University of Utah, Division of Rheumatology, Salt Lake City, UT
Background/Purpose: Fibrotic lung diseases encompass a wide spectrum of clinical entities including connective tissue disease related interstitial lung disease (CTD-ILD) and interstitial pneumonia with autoimmune…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].